During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Sophia Kamran, MD, discussed the updated AUA guidelines on salvage therapy for patients with prostate cancer and their ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly ...